Study Shows MIGS Makes up Nearly Half of Glaucoma Surgical Device Revenue

Micro-invasive glaucoma surgery (MIGS) stents are quickly becoming the norm. A new study from Market Scope titled “2019 Glaucoma Surgical Device Market Report,” shows that MIGS stents account for almost half of all glaucoma surgical device revenue in 2019. This is an even more impressive feat for the devices considering the loss of revenue that occurred from the Cypass Micro-Stent being recalled nearly a year ago. Alcon pulled Cypass off the market after five-year data revealed a higher rate of cell loss compared to patients who had cataract surgery alone. However, the report said Cypass being pulled off the market did slow down the adoption of MIGS devices and opened the door for other surgical and laser treatments. There are four FDA-approved MIGS stents: the Glaukos’s iStent and iStent inject, Allergan XEN gel stent, and Ivantis Hydrus. That number could grow as Santen Pharmaceutical’s PreserFlow MicroShunt is the next MIGS device in line for FDA approval, the report said. Earlier this year, Osaka, Japan-based Santen Pharmaceutical announced today that its U.S. subsidiary entered into a multi-year agreement whereby Glaukos will become the exclusive distributor of the MicroShunt solely in the U.S. market. Glaukos, known as the pioneer in MIGS, has been pretty busy in 2019. Earlier this month, the San Clemente, CA-based company announced it would acquire Avedro, a hybrid ophthalmic pharmaceutical and med...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news

Related Links:

This study confirms the safety and efficacy of XEN gel stents in the management of pseudoexfoliative glaucoma 2 years after implantation, with success rates similar to primary open-angle glaucoma regardless of the definition of success. Purpose: To compare the long-term safety and efficacy of XEN gel implant surgery (Allergan Inc., Irvine, CA) in patients with pseudoexfoliative glaucoma (PEXG) and primary open-angle glaucoma (POAG). Setting: Prospective, interventional study in a tertiary glaucoma center. Methods: A total of 110 eyes of 85 patients with POAG (57 eyes) or PEXG (53 eyes) and uncontrolled intraocular...
Source: Journal of Glaucoma - Category: Opthalmology Tags: Original Studies Source Type: research
Glaukos is probably at the top of its game when it comes down to maintaining a presence in the micro-invasive glaucoma surgery (MIGS) market. The San Clemente, CA-based company reaffirmed its laser-like focus on the market during a presentation at the 37th annual J.P. Morgan Healthcare Conference earlier on Wednesday. Glaukos’ CEO Thomas Burns began his presentation speaking on the strengths of the firm and its goals going forward. “Our mission is aspirational,” Burns said. “As a company we are seeking to transform glaucoma therapy, and in doing so we ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
One-year follow-up of the XEN® implant with mitomycin-C in pseudoexfoliative glaucoma patients. Eur J Ophthalmol. 2018 Aug 27;:1120672118795063 Authors: Ibáñez-Muñoz A, Soto-Biforcos VS, Chacón-González M, Rúa-Galisteo O, Arrieta-Los Santos A, Lizuain-Abadía ME, Del Río Mayor JL Abstract PURPOSE: To evaluate the intraocular pressure-lowering effect, the safety profile, and the success rate of the XEN45 Gel Stent (Allergan, Dublin, Ireland) in patients with pseudoexfoliative glaucoma. METHODS: Retrospective study conducted on patients wit...
Source: European Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Eur J Ophthalmol Source Type: research
The competition in the microinvasive glaucoma surgical (MIGS) space is certainly heating up after today’s news. FDA has given a nod to Ivantis’ Hydrus Microstent, which will undoubtedly compete against Glaukos’ iStent. Irvine,CA-based Ivantis’ approval comes on the heels of Glaukos winning a nod from FDA for the iStent inject Trabecular Micro-Bypass System. The Hydrus Microstent is used to treat patients with mild to moderate primary open-angle glaucoma in conjunction with cataract surgery. The device’s approval is based on the HORIZO...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news
Conclusions: This case report shows that fibrin formation could be an important factor in XEN gel stent obstruction, even in initially successfully filtering stents. The association of fibrinogenesis and intraocular inflammation could add a note of caution to the use of XEN gel stents in complicated cataract surgery, or advocate for aggressive anti-inflammatory treatments postoperatively. This could lead to a refinement in success predictors and better patient selection for XEN surgery. Finally, this could open the way to new management options for persistent obstructions, including pharmaceutical fibrinolysis.
Source: Journal of Glaucoma - Category: Opthalmology Tags: Case Report/Small Case Series Source Type: research
Conditions:   Glaucoma;   Ocular Hypertension Intervention:   Sponsors:   Wills Eye;   Allergan;   ASCRS Foundation (American Society of Cataract and Refractive Surgery) Enrolling by invitation
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Were The Graduate's Ben Braddock to receive a one-word bit of career advice today, it might very well be "MIGS" instead of plastics. MIGS stands for minimally invasive glaucoma surgery, and both financial analysts and developers of the tiny devices designed to treat the disease expect the market to pop for the foreseeable future. "On a scale of one through 10, I would say the market is probably somewhere between one and two in terms of maturity," said Dave Van Meter, CEO of Irvine, CA-based Ivantis. "The market in the U.S. today is probably somewhere around a couple hundred million dollars, ac...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news
More News: Allergy | Cataract Removal | Cataracts | Conferences | Eyes | Glaucoma | Japan Health | Laser Surgery | Medical Devices | Opthalmology | Study